Grants &
Scholarships

UNDERGRADUATE GRANT

Our undergraduate grant assists students to obtain experience in laboratories while performing research that aligns with CABRI’s mission. The time commitment required for assisting with lab-directed research or for working on an independent undergraduate thesis project often presents a financial burden to the undergraduate student. CABRI’s undergraduate grant can be utilized as a stipend for the student and as funds for supplies. Grants range from $2,000 – $5,000 and may be awarded as individual or group grants.

Grant Applications are now closed and will re-open in 2022. 

Please check back soon for more scholarship and grant opportunities. With questions or to request more information, please contact us

SCHOLARSHIPS

As part of our commitment to the families of individuals suffering with rare diseases, CABRI provides scholarships to college-bound students who have lost a parent to SNUC, Mastocytosis or Ichthyosis.

Criteria for eligibility:

  1. Have a parent deceased as a result of SNUC, Mastocytosis or Ichthyosis
  2. Have a demonstrated need for financial assistance
  3. Have been accepted to attend a two- or four-year accredited college or technical school

The scholarships are awarded annually based on need and availability of funds. All awards are given to the recipient for payment of tuition, fees, and other required expenses.

RESEARCH GRANT

CABRI is fully dedicated to actively researching new treatments for rare diseases. To support this endeavor, we offer research grants to specific principal investigators at academic research institutions who have a plan to extend the clinical or pre-clinical development of our mission.

Eligible applicants include domestic and international researchers alike, as well as domestic and international group collaborations. Research grants are open to investigators of any career stage who are capable of leading an independent research study and supervising personnel. Funds must be used solely for research. CABRI does not fund institutional overhead costs.

Applications may be submitted at any time during the year.

To apply for a CABRI research grant, please use our Research Proposal Application.

2021 Grant Recipients

$50k-Dr. Stefan Zwingenberger at the Center for Translational Bone, Research entitled: “Joint and Soft Tissue Research for Functionalization of biomaterials with KMN-159 to enhance bone quality in an osteoporotic drill hole model in rats.”

$75k-Dr. Floyd Chilton at the University of Arizona, Research entitled: “Impact of Circulating Secreted Phospholipase A2 Group IIA on COVID-19 and ARDS Pathogenesis, Organ Failure, and Death.”

$75,757 Dr. Laura Goodrich at Colorado State University, Research entitled: “Evaluation of the use of small novel compounds, KMN159 and KMN224, as osteogenic inducers in horse and sheep cultures” (2020, 2021).

$75k Dr. Marina Holz at New York Medical College, Research entitled: “Characterization of estrogen-mTORC1 signaling network in TSC/LAM (2020, 2021).

$70k Dr. Elias Arner of Karolinska Institute, Research entitled: “Inhibition of prostaglandin D2 biosynthesis: An unmet need in many inadequately treated diseases” (2020, 2021).

2020 Grant Recipients

$75,000- Dr. Sven-Erik Dahlen, Research entitled: “Inhibition of prostaglandin D2 biosynthesis: An unmet need in many inadequately treated diseases.” (2018, 2019, 2020.)

$60,000- Dr. Mike Holinstat, Research entitled: “ML355 regulation of platelet function, thrombosis, and bleeding in HIT” (2018, 2019, 2020.)

$50,000- Dr. Amanda Huber, Research entitled: “Mesenchymal Stem Cell specific Kdm6b regulates heterotopic ossification in Fibrodysplasia Ossifcans Progressiva.”

$15,000- David Aronoff, Research entitled: “Detection of Clostridium septicum alpha toxin by enzyme linked immunosorbent assay in an infection model” (2019, 2020.)

2019 Grant Recipients

$50,000 – Dr. Stefan Zwingenberger, University of Dresden Research entitled: “Enhancement of bone regeneration by functionalization of various bone substitution materials with a novel and potent lactam acetylene EP4 receptor agonist (KMN-159).”